Talmetoprim was studied as an intestinal antibacterial agent. However, information about the further development of the drug is not available.

Tameridone is a neurotransmitter antagonist was developed as a psychotropic agent for use in veterinary. Information about the current use of this drug is not available.

Taprostene (also known as CG 4203), a stable prostacyclin (PGI2) analog was developed by Gruenenthal as a selective agonist of the prostanoid receptor IP1. Taprostene was studied in a clinical trial in patients with acute myocardial infarction, where it was shown that the drug could be a useful adjuvant to thrombolytic agents in acute myocardial infarction. In addition, taprostene participated in a clinical trial for the treatment of critical limb ischemia, where the drug was safe and effective. Besides taprostene was studied in patients with advanced peripheral arterial disease. However, further development of the drug was discontinued.

Taniplon (also known as RU 33543), a potential anxiolytic agent that binds to benzodiazepine sites on the GABAA receptor. This drug was studied on the preclinical stage in France for the treatment of anxiety disorders. However, the further development of taniplon was discontinued.

Tazofelone (also known as LY 213829), a suppressant, is a cyclo-oxygenase 2 inhibitor that was studied for the treatment of Crohn's disease, irritable bowel syndrome and ulcerative colitis. However, Eli Lilly discontinued the further development of this compound.

CG-400549, also known as CG-0549, is an enoyl-(acyl-carrier protein) reductase fabl inhibitor developed by CrystalGenomics for the treatment of compcolicated acute and methicillin-resistant Staphylococcus aureus. CG400549 shows potent antimicrobial activity against 203 S. aureus strains and was more potent than either linezolid or vancomycin. An animal study showed that CG-400549has potential for the treatment of staphylococcal infections in mice and rats

Pentamustine is an alkylating agent that was developed for the treatment of cancer. However, information about the further development of this compound is not available.

Ciprazafone is a drug discovered in the 1980s by Pierre Fabre S.A.. It is claimed to have anxiolytic and anticonvulsant properties.